Oregon ex rel. Rosenbloom v. LG Electronics, No. 120810246, (Ore. Cir. Ct., Multnomah Cty)
Oregon filed suit against cathode ray tube (CRT) manufacturers, alleging that they illegally agreed upon the pricing of CRTs. The Attorney General filed this action on behalf of the State of Oregon and Oregon natural persons, and sought restitution, civil penalties, disgorgement and injunctive relief.
State of Wisconsin et al. v. Indivior, No. 16-5073 (E.D. Pa. Sept. 22,2016)
Plaintiff states alleged that the makers of Suboxone, a drug used to treat opioid addiction, engaged in a scheme to block generic competitors and raise prices. Specifically, they are conspiring to wtich Suboxone from a tablet version to a flim in order to prevent or delay generic entry. The states allege that the manufacturers engaged in “product hopping” in which a company makes slight changes to its product to extend patent protections and prvent generic alternatives. The complaint was filed under seal.
New York et al. v. Cephalon, No. 2:16-cv-04234 (E.D. Pa. Aug. 4, 2016)
In May 2015, the FTC settled a “pay-for-delay” suit against Cephalon for injunctive relief and $1.2 billion, which was paid into an escrow account. The FTC settlement allowed for those escrow funds to be distributed for settlement of certain related cases and government investigations. In August 2016, forty-eight states filed suit in the Eastern District of Pennsylvania against Cephalon alleging anticompetitive conduct by Cephalon to protect the profits it earned from having a patent-protected monopoly on the sale of its landmark drug, Provigil. According to the complaint, Cephalon’s conduct delayed generic versions of Provigil from entering the market for several years. The complaint alleged that as patent and regulatory barriers that prevented generic competition to Provigil neared expiration, Cephalon intentionally defrauded the Patent and Trademark Office to secure an additional patent, which a court subsequently deemed invalid and unenforceable. Before it was declared invalid, Cephalon was able to use the patent to delay generic competition for nearly six additional years by filing patent infringement lawsuits. Cephalon settled those lawsuits by paying competitors to delay sale of their generic versions of Provigil until at least April 2012. Consumers, states, and others paid millions more for Provigil than they would have had generic versions of the drug launched by early 2006, as expected. A settlement was filed with the complaint, which includes $35 million for distribution to consumers who bought Provigil.
Oregon ex rel. rosenblum v. AU Optronics Corp.
Following guilty pleas to criminal price-fixing by several LCD manufacturers, and a conviction after trial of another, Oregon filed suit against LCD manufacturers, alleging that top executives of several companies held numerous secret meetings from at least 1999 through at least 2006 for the purpose of exchanging information and setting prices on LCD panels. According to the complaint, companies such as Dell, Apple, and Hewlett Packard were among those targeted by the manufacturers’ price-fixing scheme. According to the lawsuit, the illegal overcharges were ultimately borne by state consumers and state government purchasers. The suit also alleges fraudulent concealment of the conspiracy. The lawsuit seeks monetary damages, civil penalties and injunctive relief under the Sherman Act and state antitrust statutes. A number of states filed in the MDL, but Oregon filed originally in federal district court in Oregon, and was transferred, with its consent, to the MDL. Oregon reached individual settlements with many defendants, totaling $21 million (Hitachi Displays, $565,000; Chi Mai, $1,634,600; Epson, $105,000; LG Display, $6,975,000; Sharp, $1,950,000; Samsung, $4.5 million; AU Optronics, $4.25 million; Toshiba, $525,000; HannStar, $1 million)
Maryland et al. v. Perrigo Company, No. 1:04CV01398 (D.D.C. Aug. 17, 2004)
The FTC and states alleged that the companies had entered into a “pay-for-delay” arrangement, whereby Perrigo paid Alpharma to withdraw its generic version from the market for Children’t ibuprofen.According to the complaint, in June 1998, Perrigo and Alpharma signed an agreement allocating to Perrigo the sale of OTC children’s liquid ibuprofen for seven years. In exchange for agreeing not to compete, Alpharma received an up-front payment and a royalty on Perrigo’s sales of children’s liquid ibuprofen. The FTC received $6.25 million to compensate injured consumers. The states received $1.5 million in lieu of civil penalties. the parties were enjoined from future agreements.
Oregon v 3M and SPM Settlement Agreement
The settlement resolved allegations that the companies engaged in illegal and anticompetitive practices related to bids for highway pavement marking contracts on State of Oregon projects. The state alleged that 3M, a manufacturer of pavement striping tape, and SPM, a striping contractor, exchanged information regarding bids, coordinated bids, allocated projects and provided false certifications. As a result, the state alleged that competition was reduced and the government received less advantageous terms for the purchase and installation of roadway marking products. The companies denied wrongdoing. The settlement required 3M and SPM to pay a combined $750,000 to the State of Oregon. An additional $750,000 was made available as a credit to the Oregon Department of Transportation for a total of $1.5 million. The companies also agreed to refrain from conduct that could substantially lessen competition and to provide the Department ongoing certification of compliance.
In re DDAVP Antitrust Litigation
33 states investigated “pay for delay” allegations relating to DDAVP, a drug used to alleviate bed-wetting. States alleged that Aventis, holder of the patent for the medication, engaged in a scheme to delay the regulatory approval and sale of a generic version of DDAVP, in violation of state and federal antitrust law. States and defendants entered into a settlement under which states received $3.45 million, not as a civil penalty and defendants did not admit guilt.
Oregon ex rel. Myers v. Monem, No. 07c17510 (Ore. Cir. Cty, Marion Cty. 2007)
Defendant Monem was employed by state Dept. of Corrections as purchaser of food. Monem accepted bribes from several food wholesalers to purchase food for the prison system. USDOJ sought civil forfeiture of some of defendants’ assets. State brought state RICO, bribery and antitrust claims. Judgment was entered against defendants in the amount of $4,556,103 and property held by corporations they had set up was sold in partial judgment on that claim.
Oregon ex rel. Kroger v. Kumar, No. 0903806CV, (Or. Cir. Ct., Klamath Cty. Feb. 5, 2010)
Defendants owned a retail market that sells fuel. State alleged that the defendants used threats and intimidation to seek to fix the price of gas at Ray’s Market and Klamath River Gas, a nearby station. State also alleged violations of its consumer protection act because the advertised price of gas was less than what was charged at the pump. Defendants were enjoined from future violations and paid $5,000, which the state agreed to accept in lieu of the $25,000 award.
Texas et al. v. Organon (Remeron), No. 04-5126 (D.N.J. 2004)
Plaintiff states settled with drug maker Organon USA, Inc. and its parent company, Akzo Nobel N.V., resolving antitrust claims involving the antidepressant drug Remeron between June 2001 and October 2004. The states’ complaint alleged that Organon unlawfully extended its monopoly by improperly listing a new “combination therapy” patent with the U.S. Federal Drug Administration. In addition, the complaint alleged that Organon delayed listing the patent with the FDA in another effort to delay the availability of lower-cost generic substitutes. The $26 million settlement resolved claims brought by state attorneys general, as well as a private class action brought on behalf of a class of end payors. Organon also agreed to make timely listings of patents and to submit accurate and truthful information to the FDA.
